MRK - Merck & Co., Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
73.31
-0.78 (-1.05%)
As of 10:28AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close74.09
Open73.50
Bid73.57 x 300
Ask73.58 x 900
Day's Range73.24 - 73.79
52 Week Range52.83 - 75.99
Volume1,505,252
Avg. Volume10,171,918
Market Cap190.634B
Beta (3Y Monthly)0.60
PE Ratio (TTM)151.15
EPS (TTM)0.49
Earnings DateJan 31, 2019 - Feb 4, 2019
Forward Dividend & Yield2.20 (2.94%)
Ex-Dividend Date2018-12-14
1y Target Est79.12
Trade prices are not sourced from all markets
  • MARKETS: Stocks could bounce here, but I'm selling the rally
    Yahoo Finance Video38 minutes ago

    MARKETS: Stocks could bounce here, but I'm selling the rally

    Risk markets continue to deliver mixed messages to traders and market participants. The latest price action suggests more downside -- but first -- with a possible bounce to the 2750 level in the S&P 500, says Yahoo Finance's Jared Blikre, who breaks it down with Jen Rogers and Myles Udland. Here's the month-to-date performance of the components of the Dow Jones Industrial Average as of 11/14/2018: PG Procter & Gamble Co -0.21% VZ Verizon Communications -0.60% KO Coca-Cola Co -0.38% AXP American Express Co -0.73% DIS Disney (Walt) Co -0.43% JNJ Johnson & Johnson -1.01% MRK Merck & Co -0.68% WBA Walgreen Boots Alliance Inc -0.37% MCD McDonald's Corp -0.79% DWDP DowDuPont Inc 0.03% UTX United Technologies -0.93% CAT Caterpillar Inc 0.39% MMM 3M Co 0.14% NKE Nike Inc Cl B -2.11% INTC Intel Corp 0.25% IBM Intl Business Machines Corp 0.05% V Visa Inc -0.35% PFE Pfizer Inc -0.52% CVX Chevron Corporation -1.78% HD Home Depot Inc -1.55% $INDU Dow Jones Industrial Average -0.47% JPM JPMorgan Chase & Co 0.77% WMT Wal-Mart Stores -1.31% UNH UnitedHealth Grp Inc -0.83% MSFT Microsoft Corp 0.36% XOM Exxon Mobil -1.19% CSCO Cisco Systems 4.17% TRV The Travelers Companies Inc -0.23% BA Boeing Co -1.19% AAPL Apple Inc 0.99% GS Goldman Sachs Grp -0.14%

  • Merck (MRK) Stock Moves -0.7%: What You Should Know
    Zacks17 hours ago

    Merck (MRK) Stock Moves -0.7%: What You Should Know

    Merck (MRK) closed the most recent trading day at $74.09, moving -0.7% from the previous trading session.

  • AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
    Zacks19 hours ago

    AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study

    AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.

  • Merck Starts Rolling BLA Submission for Ebola Vaccine V920
    Zacksyesterday

    Merck Starts Rolling BLA Submission for Ebola Vaccine V920

    Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.

  • Can These 2 Battered Biotech Stocks Recover?
    Motley Foolyesterday

    Can These 2 Battered Biotech Stocks Recover?

    These oncology pioneers have lost more than half their value in the past six months.

  • Benzingayesterday

    The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 13) AstraZeneca plc (NYSE: AZN ) Down In The Dumps (Biotech ...

  • Reutersyesterday

    Merck drug Keytruda succeeds in late-stage esophageal cancer trial

    Merck & Co's blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday. Keytruda, among a class of medicines called PD-1 inhibitors, is Merck's top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer. Keytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.

  • Business Wireyesterday

    Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

    With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients

  • Don’t Be Fooled by the Recent Selling; Hedge Funds Still Love Merck & Co., Inc. (MRK)
    Insider Monkeyyesterday

    Don’t Be Fooled by the Recent Selling; Hedge Funds Still Love Merck & Co., Inc. (MRK)

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]

  • GuruFocus.com2 days ago

    Daniel Loeb Purchases 7 Stocks in 3rd Quarter

    Third Point's buying slows as it seeks 'compounders of value'

  • Business Wire2 days ago

    Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

    Merck (MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease. This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by the company in July 2016.

  • Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates
    Zacks2 days ago

    Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates

    Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.

  • 5 Stocks to Sell After the Midterm Election
    InvestorPlace3 days ago

    5 Stocks to Sell After the Midterm Election

    After Democrats obtained a narrow majority in the House of Representatives in the midterm elections, both House Democrats and President Trump will likely be looking to make at least some deals. To retain their majority, House Democrats will have to convince moderate voters in the swing districts that Democrats narrowly won that they are moderate and can be productive. For his part, President Trump will likely have to convince at least some moderate voters, i.e., centrist suburban women and independents that he can make deals that will make the country and their lives better.